CAR-T Therapy Pipeline Landscape Report, 2024 - Features Insights on Emerging Drugs CT053, Descartes-08, ALLO-501A, CTX110, and IMPT 314 [Yahoo! Finance]
CASI Pharmaceuticals, Inc. - Ordinary Shares (CASI)
Last casi pharmaceuticals, inc. - ordinary shares earnings: 11/12 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
casipharmaceuticals.com/investor-relations
Company Research
Source: Yahoo! Finance
This report provides in-depth insights into the CAR-T therapy pipeline, revealing extensive research and development activities in this dynamic field. The report showcases the collective efforts of over 200 companies with more than 252 pipeline drugs at various stages of clinical and nonclinical development. This report is foundational for understanding the current landscape and future directions of CAR-T therapy innovation. Advanced Therapeutic Development With the aim of revolutionizing cancer treatment, the report emphasizes the advancements in CAR-T therapy - a form of immunotherapy where T cells are genetically engineered to better recognize and combat cancer cells. It highlights efforts to overcome current technological limitations, enhance safety profiles, and explore novel applications beyond oncology, including autoimmune and inflammatory diseases. Therapeutic Assessment and Pipeline Development Activities The extensive therapeutic assessment covered in the report ex
Show less
Read more
Impact Snapshot
Event Time:
CASI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CASI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CASI alerts
High impacting CASI Pharmaceuticals, Inc. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
CASI
News
- CASI Pharmaceuticals (NASDAQ:CASI) shareholders are still up 129% over 1 year despite pulling back 22% in the past week [Yahoo! Finance]Yahoo! Finance
- CASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCEPR Newswire
- CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2024 BUSINESS AND FINANCIAL RESULTSPR Newswire
- CASI Pharmaceuticals, Inc. (NASDAQ: CASI) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- CASI Pharmaceuticals, Inc. (NASDAQ: CASI) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
CASI
Earnings
- 8/16/24 - Beat
CASI
Sec Filings
- 9/12/24 - Form 6-K
- 9/4/24 - Form EFFECT
- 8/29/24 - Form F-3/A
- CASI's page on the SEC website